Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2018

View Archived Issues

T-cell bispecfic antibody against p95HER2 mediates on-target killing of tumor cells

Pegfilgrastim biosimilar INTP-5 bioequivalent to Neulasta

Pancreatic islet cells express "innate immune" protein

Zafgen presents interim analysis results from phase II study of ZGN-1061

Acurx and WuXi collaborate to advance the development of first-in-class antibiotics

Vedolizumab may help eliminate HIV infection by attenuating lymphoid aggregates

Zika virus persists in serum for over 7 months after disease onset

Resistance drives convergence onto SCNC

Innate immune inhibition fights glaucoma

Pulmocide presents phase I safety and pharmacokinetic data for PC-786

JNJ-8678 demonstrates early antiviral effect in RSV-infected infants

Phase II data presented for serlopitant as treatment for refractory chronic cough

Green Cross initiates phase II study of high-dose quadrivalent influenza vaccine GC-3114

Genzyme recruits patients at risk of rapidly progressive ADPKD in phase II/III study of GZ-402671

Amicus and University of Pennsylvania establish gene therapy collaboration

Metabolic control seen in high-fat diet-fed mice by a novel hybrid peptide

Phase III study of Otezla in moderate to severe scalp psoriasis meets primary endpoint

Exelixis initiates phase III study of cabozantinib in radioiodine-refractory DTC

Affimed places AFM-11 program on clinical hold

VBI-1501 demonstrates safety and immunogenicity in first-in-human study

FDA issues complete response letter for Acacia's Barhemsys

FDA approves IND for first-in-human study of Coordination's CPI-100

Nosopharm develops synthetic odilorhabdins with good safety and potent antibacterial activity